Eli Lilly & Co., the drugmaker in its worst year of declining sales, reported profit that matched analysts’ estimates as gains from its animal health unit helped offset declining pharmaceutical revenue.
The U.S. government needs to open its borders to attract and retain talented scientists for drugmakers to employ, Eli Lilly & Co. Chief Executive Officer John Lechleiter plans to tell a technology conference today.
Eli Lilly & Co. Chief Executive Officer John Lechleiter said during a panel discussion in Washington that U.S. lawmakers should renew the research-and- development tax credit to make it easier for companies to compete globally. The Oct. 5 event, sponsored by Harvard University and the Business Roundtable and hosted by Bloomberg News in Washington, centered on ways to spur innovation.
Eli Lilly & Co., the drugmaker projected to hit a six-year low in revenue this year, reported profit that beat analysts’ estimates as sales gains in other products blunted a decline for its top-seller, Cymbalta.